Page 88 - Libro Memoria Cien Inglés

Within the Molecular Genetics de- • Platelets-rich plasma (PRP)
partment, the activity of the Vallecas • Platelets-free plasma (PFP)
Project is shown in the table on the
following page: • Buffy Coat (BC)
• Red blood cells (RBC)
The type of primary aliquots that are
obtained in duplicate are the following: • Mononucleate leukocytes

• Serum
• Whole blood (ST, for its acronym in
Spanish)

Genomic DNA was extracted from whole blood of all participants who have signed
informed consent to it and the APOE gene, an important marker of genetic risk for
Alzheimer's disease, was analyzed. The comparison of the frequency of APOE allele
4 carriers between CAFRS patients and Vallecas Project volunteers confirms the
risk to suffer from Alzheimer's disease with an OR = 3.53 (p <0.001). In addition, in
order to define different subpopulations of genetic risk, other possible genetic sus-
ceptibility genes have also been analyzed in a subset of participants (see below).

APOE GENOTYPES n
e2/e2 5

e2/e3 118
e2/e4 10

e3/e3 848
e3/e4 195
e4/e4 12

Distribution of genotypes of APOE gene in the population of volunteers from the
Vallecas Project.

It is also important to emphasize that various projects related to neurode-
the samples obtained from Vallecas generative diseases, especially Alzhei-
Project volunteers aged between 70 mer's disease. The monitoring for a
and 85 years (at the baseline evalua- period of 5 years will allow us to detect
tion) that include a comprehensive early, even before clinical symptoms
assessment of cognitive, sociological manifestation, susceptibility factors
and neuroimaging state are optimal and biomarkers associated with Alzhei-
for its use as a control population in mer's disease.

Annual report Fundación CIEN 2020 88